Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb).
Journal Information
Full Title: Ther Adv Med Oncol
Abbreviation: Ther Adv Med Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"RJ, NA, and DS are employees and shareholders of Amgen Inc. ASO, LSL, and GB are employees of ConcertAI, which received funding from Amgen Inc. for the conduct of this study. JHG is a consultant for Amgen and is a speaker for G1 Therapeutics and BMS."
Funding Disclosure
Evidence found in paper:
"Funding: This study was funded by Amgen Inc., Thousand Oaks, CA."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025